Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.
Aged
Anti-Bacterial Agents
/ therapeutic use
Aortic Valve
/ microbiology
Cephalosporins
/ therapeutic use
Colistin
/ pharmacology
Compassionate Use Trials
Drug Resistance, Multiple, Bacterial
Endocarditis, Bacterial
/ drug therapy
Female
Humans
Microbial Sensitivity Tests
Pseudomonas Infections
/ complications
Pseudomonas aeruginosa
/ drug effects
Treatment Outcome
beta-Lactamases
Cefiderocol
Pseudomonas aeruginosa
cefiderocol
drug resistance
endocarditis
microbial
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
17 05 2019
17 05 2019
Historique:
received:
10
09
2018
accepted:
08
11
2018
pubmed:
13
11
2018
medline:
5
8
2020
entrez:
13
11
2018
Statut:
ppublish
Résumé
Serious infections such as endocarditis due to extremely drug-resistance gram-negative bacteria are an increasing challenge. Here, we present successful adjunctive use of cefiderocol for a patient with persistently bacteremic healthcare-associated native aortic valve endocarditis due to an extended-spectrum beta-lactamase-positive Pseudomonas aeruginosa susceptible in vitro only to colistin, following failure of conventional therapeutic options.
Identifiants
pubmed: 30418554
pii: 5174241
doi: 10.1093/cid/ciy963
pmc: PMC6522681
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
beta-Lactamases
EC 3.5.2.6
Colistin
Z67X93HJG1
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1932-1934Informations de copyright
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Korean J Intern Med. 2012 Jun;27(2):128-42
pubmed: 22707882
J Microbiol Immunol Infect. 2016 Aug;49(4):516-22
pubmed: 25442867
Clin Microbiol Rev. 2015 Apr;28(2):337-418
pubmed: 25788514
Infect Dis (Lond). 2015;47(12):889-95
pubmed: 26260729
Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34
pubmed: 26574013
BMC Infect Dis. 2016 Aug 20;16(1):431
pubmed: 27543116
Antimicrob Agents Chemother. 2016 Dec 27;61(1):
pubmed: 27795374
J Clin Pharmacol. 2017 May;57(5):584-591
pubmed: 27874971
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630181
Expert Opin Investig Drugs. 2018 Feb;27(2):193-197
pubmed: 29318906
Int J Antimicrob Agents. 2018 Aug;52(2):301-302
pubmed: 29580931
Lancet Infect Dis. 2018 Dec;18(12):1319-1328
pubmed: 30509675